[go: up one dir, main page]

FR3062303B1 - Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide - Google Patents

Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide Download PDF

Info

Publication number
FR3062303B1
FR3062303B1 FR1750853A FR1750853A FR3062303B1 FR 3062303 B1 FR3062303 B1 FR 3062303B1 FR 1750853 A FR1750853 A FR 1750853A FR 1750853 A FR1750853 A FR 1750853A FR 3062303 B1 FR3062303 B1 FR 3062303B1
Authority
FR
France
Prior art keywords
diol
cannabinoid compound
liquid vaporizable
vaporizable formulation
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1750853A
Other languages
English (en)
Other versions
FR3062303A1 (fr
Inventor
Antoine Piccirilli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Ceres Fr
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR1750853A priority Critical patent/FR3062303B1/fr
Publication of FR3062303A1 publication Critical patent/FR3062303A1/fr
Application granted granted Critical
Publication of FR3062303B1 publication Critical patent/FR3062303B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

[0001] Formulation liquide vaporisable comprenant au moins un composé cannabinoïde et au moins un diol choisi parmi les diols de Formule (I) : dans laquelle : R1 et R2 sont identiques ou différents, et sont choisis dans le groupe constitué par un atome d'hydrogène (-H) ou radical alkyle comprenant de 1 à 2 atomes de carbone ; m+n=1 ou m+n=2 ; n=0 ou n=1 ou n=2 ; - m=0 ou m=1 ; le diol étant sous forme de mélange d'isomères et/ou d'isomère isolé lorsqu'il comprend un ou plusieurs atomes de carbone asymétrique.
FR1750853A 2017-02-01 2017-02-01 Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide Active FR3062303B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1750853A FR3062303B1 (fr) 2017-02-01 2017-02-01 Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1750853A FR3062303B1 (fr) 2017-02-01 2017-02-01 Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide
FR1750853 2017-02-01

Publications (2)

Publication Number Publication Date
FR3062303A1 FR3062303A1 (fr) 2018-08-03
FR3062303B1 true FR3062303B1 (fr) 2019-11-29

Family

ID=59974492

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1750853A Active FR3062303B1 (fr) 2017-02-01 2017-02-01 Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide

Country Status (1)

Country Link
FR (1) FR3062303B1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3745884A1 (fr) 2018-01-31 2020-12-09 Canopy Holdings, Llc Poudre de chanvre
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20220000764A1 (en) * 2018-11-06 2022-01-06 Columbia Care Llc Stabilized terpene-enriched cannabinoid extract and methods of use thereof
FR3113563B1 (fr) * 2020-09-03 2025-05-02 Cids France Utilisation des phytocannabinoïdes végétaux extraits par méthode de distillation pour la fabrication de e-liquides
US20220280447A1 (en) * 2021-03-05 2022-09-08 Health Via Modern Nutrition Inc. Compositions and methods for improving brain function
US12059398B2 (en) 2022-08-26 2024-08-13 Health Via Modern Nutrition Inc. Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2441963T3 (es) * 2007-10-05 2014-02-07 Sti Pharmaceuticals Ltd. Composición farmacéutica

Also Published As

Publication number Publication date
FR3062303A1 (fr) 2018-08-03

Similar Documents

Publication Publication Date Title
FR3062303B1 (fr) Formulation liquide vaporisable comprenant au moins un diol et au moins un compose cannabinoide
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
EP4458348A3 (fr) Compositions pharmaceutiques contenant des dérivés de pyridone polycycliques substitués et promédicament de ceux-ci
RU2487124C2 (ru) Новое амидное производное и его использование в качестве лекарственного средства
MX2024010631A (es) Derivados ciclicos de panteteina y usos de los mismos
ATE322264T1 (de) Medizinische zusammensetzungen als begleittherapie gegen krebs
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
BRPI0502578A (pt) composições contendo agentes antiacne e uso das mesmas
SE0201544D0 (sv) Novel compounds and thier use
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
MA27897A1 (fr) Compose de glucocorticosteroide specifique presentant une active anti-inflammatoire
JP2016518385A5 (fr)
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
JP2005533897A5 (fr)
MA41790B1 (fr) Dérivé de morphinane
TW200612920A (en) Novel imidazolidine derivatives
KR920016454A (ko) 환-치환된 2-아미노-1,2,3,4-테트라하이드로나프탈렌 및 3-아미노크로만
MA42781B1 (fr) Composés étheramines et leur utilisation en tant que collecteur de flottation
MA31620B1 (fr) Perfectionnements de ou concernant des composes organiques
EP2202222A3 (fr) Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments
MX393004B (es) Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene.
FR2950807B1 (fr) Composition cosmetique contenant des liposomes encapsules dans un compose oxazolidin-2-one
MX2020013729A (es) Compuestos de cianotriazol y usos de los mismos.
FR3020809B1 (fr) Derives de 4-vinyl-2cyclopentene-1-one leur preparation et leur utilisation en tant qu'agent antibiotique
WO2014111563A3 (fr) Composition cosmétique ou dermatologique comprenant une mérocyanine et un agent anti-uv à base de benzotriazole et/ou un composé bis-résorcinyl triazine

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180803

PLFP Fee payment

Year of fee payment: 3

TP Transmission of property

Owner name: LABORATOIRES CERES, FR

Effective date: 20190809

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9